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Abstract
Summary A simulation model adopting a health system
perspective showed population-based screening with DXA,
followed by alendronate treatment of persons with osteo-
porosis, or with anamnestic fracture and osteopenia, to be
cost-effective in Swiss postmenopausal women from age
70, but not in men.
Introduction We assessed the cost-effectiveness of a popula-
tion-based screen-and-treat strategy for osteoporosis (DXA
followed by alendronate treatment if osteoporotic, or osteo-
penic in the presence of fracture), compared to no interven-
tion, from the perspective of the Swiss health care system.
Methods A published Markov model assessed by first-order
Monte Carlo simulation was refined to reflect the diagnostic
process and treatment effects. Women and men entered the
model at age 50. Main screening ages were 65, 75, and
85 years. Age at bone densitometry was flexible for persons
fracturing before the main screening age. Realistic assump-
tions were made with respect to persistence with intended
5 years of alendronate treatment. The main outcome was cost
per quality-adjusted life year (QALY) gained.
Results In women, costs per QALY were Swiss francs
(CHF) 71,000, CHF 35,000, and CHF 28,000 for the main
screening ages of 65, 75, and 85 years. The threshold of
CHF 50,000 per QALY was reached between main
screening ages 65 and 75 years. Population-based screening
was not cost-effective in men.
Conclusion Population-based DXA screening, followed by
alendronate treatment in the presence of osteoporosis, or of
fracture and osteopenia, is a cost-effective option in Swiss
postmenopausal women after age 70.
Keywords Alendronate . Bone densitometry . Cost-utility
analysis .Modelling studies . Osteoporosis . Switzerland
Introduction
Osteoporosis is a chronic, systemic disease, characterised
by low bone mass and deterioration of bone micro-
architecture, leading to increased fracture risk [1]. Osteo-
porotic fragility fractures may occur at any skeletal site [2].
However, fractures of the hip, the spine and the distal
forearm are the most frequent osteoporotic fracture types
[3], representing 82% and 75% of all incident osteoporotic
fractures in Swiss women and men, respectively [4]. The
lifetime risk of any osteoporotic fracture approximates 50%
in women and 20% in men [5]. Fractures result in
significant morbidity [6, 7], mortality [8, 9], and reductions
in quality of life [10].
Osteoporosis has a profound and growing impact on
health care resource utilization, especially in industrialized
countries. The direct expenditures for the treatment of
osteoporotic fractures were estimated at US dollar (USD)
10–15 billion per year for the USA [11], a figure which is
consistent with Swiss francs (CHF) 713 million reported for
Switzerland for the year 2000 [4]. These costs are expected
to substantially increase in the coming decade, due to the
overall ageing of the population and to the exponential
increase of fracture incidence with age [4, 12].
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Drug therapy of osteoporosis is generally indicated in
patients who have had a prior fragility fracture and in
patients who have osteoporosis according to the WHO
densitometric definition (i.e., T-score≤−2.5 SD) [1].
Alendronate, an aminobisphosphonate, has been previously
shown, in randomised controlled primary endpoint fracture
trials [13–15] and in meta-analyses of such trials [16, 17],
to reduce fracture risk at all clinically relevant sites,
including the hip, in postmenopausal women with osteo-
porosis defined as low BMD with or without prevalent
vertebral fractures. In addition, the efficacy and safety of
long-term treatment of osteoporosis with alendronate was
established for up to 10 years of continuous therapy [18].
Furthermore, the efficacy profile of alendronate for reduc-
ing fracture risk was established in men with primary
osteoporosis [19, 20] and in the most frequent form of
secondary osteoporosis, glucocorticosteroid-induced osteo-
porosis, in women and in men [21].
Several studies have suggested that the treatment of
osteoporosis with alendronate is cost-effective [22–30] with
an incremental cost-utility ratio (ICUR) of less than USD
50,000 per quality adjusted life year (QALY) gained.
However, these studies generally did not consider the cost
involved with the identification of cases of osteoporosis
which deserve therapeutic intervention, with only two
exceptions, one study in glucocorticosteroid-induced oste-
oporosis [30] and one recent publication by Schousboe et
al. [27]. In the latter work, the health benefits and costs of
universal screening of elderly women, followed by alendro-
nate treatment of those identified with osteoporosis
(screen-and-treat strategy) were assessed from the societal
perspective. The cost per QALY gained was estimated at
USD 43,000 and USD 5,600 for 65 and 75-year-old
women, respectively, while the intervention was found to
be cost-saving for older women [27]. However, this model
observed the screened populations from the age of mass
screening onwards only and did not take into account the
effect of cases identified and treated earlier (e.g., due to
fractures occurring before the main screening age).
In Switzerland, as in many other European countries,
bone densitometry with DXA is not accepted for mass
screening of osteoporosis and reimbursement is limited to
indications resulting from case-finding strategies. Drug
treatment is reimbursed for persons with a T-score≤
−2.5 SD or in the presence of one or more fragility
fractures. Whether and for which subset of the population
mass screening with DXA, followed by drug treatment
where indicated, would be cost-effective remains unknown.
Using an adapted version of our published model [12],
the present study aimed at assessing the cost-effectiveness
of mass bone densitometry screening plus subsequent
alendronate therapy, compared to no drug treatment of
osteopenia and osteoporosis, in the Swiss population from
age 50 onwards, from the perspective of the Swiss health
care system. We took into account the impact of earlier
fracture events, which have already led to “pre-screening
age” diagnostic activities. We hypothesized that even if the
diagnostic process is taken into account in the modelling,
the cost-effectiveness of subsequent drug intervention will
still be preserved in specific patient groups.
Materials and methods
The cost-effectiveness of two alternative strategies was
evaluated in a simulation-based incremental cost-utility
analysis from the perspective of the Swiss health care
system. For this purpose, a non-intervention strategy was
compared to a screen-and-treat strategy defined as i) bone
densitometry screening with DXA at a predefined main
screening age or if a fracture occurred after age 50, and ii)
alendronate (FOSAMAX®; Merck & Co) treatment in
subjects with osteoporosis (T-score≤−2.5 SD), or with
confirmed osteopenia (T-score > −2.5 SD but < −1.0 SD)
after a fracture event [31]. The time horizon for analysis
was life-long from age 50 on in the main analysis. Direct
medical costs were taken into account regardless of payer.
For women and men, the outcomes of the screen-and-
treat strategy were assessed for main screening ages of 65,
75, and 85 years, and for three treatment options each:
treatment with alendronate for 5 years [25] with full
persistence (to assess the theoretical potential); treatment
with alendronate for 5 years with realistic persistence; and
treatment with alendronate for 10 years with realistic
persistence.
Additional specifications were: re-screening once after
3 years if osteopenic at first measurement (in the absence of
fracture); assessment of all persons presenting with a
fracture and treatment if osteopenic or osteoporotic;
treatment initiation without additional screening if a
fracture occurred and an earlier screening had already
confirmed the presence of osteopenia; no repeated initiation
of alendronate treatment in the same person; no initiation of
treatment after age 95.
The main outcome was the incremental cost per QALY
gained (incremental cost-utility ratio; ICUR) of each
screen-and-treat scenario vs. the no intervention scenario.
In the absence of an accepted cost-effectiveness thresh-
old for Switzerland, ICUR results of less than CHF 50,000
per QALY gained were regarded as cost-effective. Taking
different price structures into account [32], one can regard
this choice as roughly equivalent to the thresholds of USD
50,000 per QALY, and of British pound (GBP) 20,000–
30,000 per QALY, which have been used for the USA and
the United Kingdom, respectively [33, 34]. CHF 1 equalled
USD 0.80 on June 30, 2006.
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Model characteristics
Key model characteristics were previously described [12].
Briefly, a Markov state transition model with four mutually
exclusive health states (alive without fracture; alive with at
least one distal forearm or vertebral fracture, but no hip
fracture; alive with at least one hip fracture; dead) was
developed to simulate the number of osteoporotic hip,
vertebral, and distal forearm fractures as a function of
demographic change and other influences. This model was
analysed using individual, first-order Monte Carlo simula-
tion, and was pre-designed to be adaptable for assessing the
impact of different screening, prophylactic, and treatment
strategies on fracture occurrence and associated cost,
allowing for a wide variety of scenarios regarding planned
medication usage, drug efficacy, and individual persistence
with treatment. Cycle length was one month. For the
purpose of this study, the model was adapted as follows:
1. The increase in relative fracture risk observed in
persons with a history of previous fracture; in those
suffering from osteopenia or osteoporosis; and in
nursing home residents was additionally modelled.
The technical implementation was such that the average
gender- and age-specific fracture incidences remained
unaffected.
2. The probability of having osteopenia or osteoporosis at
model entry, or of developing any of these conditions,
was modelled using gender- and age-specific preva-
lence estimates and transition probabilities derived
from these.
3. The impact of alendronate usage was modelled using
published relative risks (RRs).
4. Age at model entry was kept constant while screening
age was considered variable in the different scenarios,
in order to accommodate for the fact that at a given
main screening age, some persons may already have
been identified with and treated for osteoporosis.
5. In order to take into account the difference between
fracture-associated mortality and mortality causally
related to fracture, the estimates of life years gained
through alendronate usage were corrected downwards
in a separate step, outside the main model. The “life
expectancy component” of the QALY results was
corrected in the same way.
Model inputs
Published or publicly available Swiss data sources were used
whenever available. Otherwise, European data were preferred
to US data, and were adjusted for regional differences within
Europe. Gender- and age-specific population-level fracture
risks and other models inputs used in the previously published
model version were retained with the exception of osteopo-
rosis attribution probabilities, which were no longer used to
model osteoporotic causation of fracture events [12]. Addi-
tional inputs comprised the following.
Prevalence of osteopenia/osteoporosis was assumed to
be similar as seen in the NHANES III study for a caucasian
US population, based on femoral neck BMD measurements
[35, 36]. In the absence of published Swiss BMD data, a
local DXA reference database from the Bern Canton
supported this assumption. Technical implementation used
the results of the Rotterdam Study, with data points
available for both genders and all relevant age groups
[37]. Compared with NHANES III, the Rotterdam data
showed a higher prevalence, consistent with the north-south
gradient of osteoporosis prevalence in Europe. Therefore, a
downwards adjustment was performed, using the following
correction factors: 0.80 for osteopenia and osteoporosis in
women; 0.65 for osteoporosis and 0.75 for osteopenia in
men. This resulted in average prevalences of 23% and 8%
(osteoporosis), and of 49% and 46% (osteopenia), in women
andmen from age 50, respectively. These figures are consistent
with the NHANES III results [35, 36]. The incidence of
osteopenia and osteoporosis was estimated using transition
probabilities derived from these prevalence data.
Prevalence of any previous fracture was derived from a
recent meta-analysis exploring the relationship of any
previous fracture with age, sex and bone mineral density
in 15,259 men and 44,902 women from 11 cohorts
followed for a total of 250,000 person-years [38].
Relative fracture risks In the presence of osteoporosis or
osteopenia, RRs of 2.7 or 1.3, respectively, as reported in
the Rotterdam Study, were used for non-vertebral fractures
in women and men [37]. Identical RRs were assumed for
vertebral fractures [39]. BMD-adjusted RRs of 1.7 for
women and of 2.0 for men were used to take into account
the presence of previous fracture [38]. For nursing home
residents, a RR for hip fracture of 3.5 was assumed, based
on the only recent Swiss publication available [40]. This
figure is consistent with previously published Swiss [41]
and US data [42, 43]. No increased risk of vertebral and
distal forearm fracture was assumed for this group [44, 45].
The above RRs compare persons who have the risk factor
of interest with persons who do not have it. In combination
with absolute fracture risk (gender- and age-specific, but
averaged across other risk factors), and gender- and age-
specific patterns of risk factor prevalence, they provided a
basis for deriving individualised fracture risks as they were
finally used in the modelling.
The RR of fracture during alendronate treatment in
women with osteoporosis was generally assumed to be 0.5,
in accordance with published primary endpoint trials and
Osteoporos Int (2007) 18:1481–1491 1483
meta-analyses [13–17, 28]. However, a more conservative
RR of 0.6 was assumed for non-vertebral fractures after age
85 [29, 46]. In women with osteopenia, the RR was
conservatively assumed to be 0.7 for vertebral fractures
[15] and 1.0 for other fractures. Identical assumptions were
used for men [20]. The effect of alendronate has been shown
to be present early in treatment [47]. For the purpose of this
analysis, it was assumed to be present from day 1 of therapy,
given that the above RR estimates represent averages across
the entire observation periods of the underlying studies. After
the end of alendronate administration, we assumed a linear
decline of the alendronate effect to zero over a 5-year period
[18, 48], or over a period equal to the given person’s
treatment duration, whichever was shorter.
Persistence with alendronate treatment was assumed to
decline linearly from 100% to 65% during year 1 and from
65% to 45% between end of year 1 and the end of the
intended duration of use [49]. It was assumed that those
who stopped drug treatment prematurely did no longer
accrue drug costs.
Mortality Twenty-five percent of the deaths associated with
hip fracture were considered to be causally related in the
base case scenario [50]. Consequently, the life years gained
through alendronate usage, as reported by the model, were
multiplied with a correction factor of 0.25. No such
adjustment was made for vertebral fracture-associated
excess deaths whose number was considered to be too
low to meaningfully impact on the overall results, espe-
cially when compared to the remaining uncertainty about
hip fracture-related excess mortality [48, 51]. To account
for an increased general morbidity of persons admitted to
nursing homes, in the absence of published data, a
correction factor of 0.9 was applied to the crude hip
fracture-related extra time spent in nursing homes, for the
base case analysis.
Utilities associated with health states As no Swiss data
were available, population-based European (Danish) data
were used as shown in Table 1 [23, 52]. These baseline
utilities were adjusted downwards after fracture occurrence,
by applying multiplication factors as reported by Kanis et
al. (Table 2) [53]. It was assumed that 2nd year factors
would also apply for subsequent years. In addition, 1st
year and subsequent years factors for the combination of a
hip and a clinical vertebral fracture were assumed to be
0.489 and 0.714 [27, 54]. Utility and multiplication factor
measurements involved the time trade off method and the
EQ-5D [52–54].
Costs Unit cost estimates were real cost estimates for the
year 2000. The monthly cost of alendronate treatment was
set at CHF 61.36, based on the public price of marketed
alendronate in Switzerland in 2005 adjusted for the health
system-specific price inflation between 2000 and 2005 of
3.4%, as published by the Swiss Federal Office of Statistics
(SFOS). Based on expert opinion and Swiss tariff lists, the
cost of each screening episode was estimated at CHF 300,
covering bone densitometry and a medical consultation
with typical services performed. Daily inpatient costs were
CHF 1,009 for acute care hospitals, CHF 440 for inpatient
rehabilitation facilities, and CHF 187 for nursing homes, as
reported by the SFOS for the year 2000. Overall inpatient
costs were modelled individually as previously described
[12]. To give some reference points, average acute care
length of stay was 17.4 days for hip fracture, 18.0 days for
vertebral fracture and 6.4 days for distal forearm fracture.
The probability of being hospitalised was assumed to be
33% after a vertebral fracture coming to clinical attention
[3, 55] and 53% after a distal forearm fracture [12].
Participation in an inpatient rehabilitation program after
hip fracture was assumed to occur in 68% of women and
36% of men, with a length of stay of 59 and 54 days,
respectively [56]. Ambulatory treatment costs post fracture
was estimated at CHF 6,442 for a hip fracture, based on
published data [57]. They were estimated at CHF 2,250 for
a vertebral fracture and at CHF 1,750 for a distal forearm
fracture, irrespective of whether an initial hospitalisation
Table 1 European (Danish) population utility values1
Age Average utility
50 0.917
55 0.9199
60 0.8992
65 0.8882
70 0.8939
75 0.863
80 0.8529
85 0.8339
1 Pedersen et al. 2003 [23, 52].
Table 2 Utility correction factors
Fracture site Female,
1st year
Male,
1st
year
Female,
subsequent
years
Male,
subsequent
years
Wrist1 0.977 0.977 0.999 0.999
Vertebrae1 0.820 0.777 0.913 0.912
Hip1 0.792 0.792 0.813 0.813
Hip and clinical
vertebral
fracture2
0.489 0.489 0.714 0.714
1 Kanis et al. 2004 [53].
2 Estimated based on Tosteson et al. 2001 [54] and Schousboe et al.
2005 [27].
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occurred. These estimates were based on expert opinion as
there were no published Swiss data available.
Discount rate The discount rate for costs and QALYs was
set at 3%.
Sensitivity analysis
In the base case scenarios, model entry was at age 50 for all
persons, which allowed to take into account the impact of
cases of osteoporosis or osteopenia with intercurrent
fracture, identified before the main screening age. In
alternative scenarios, intended for comparison purposes,
the simulated persons entered the model at the main
screening age, i.e., their previous diagnosis and treatment
history was neglected.
Additional, univariate sensitivity analyses were con-
ducted to identify influential input parameters. Specifically,
average population fracture risks; the risk reduction
achieved with alendronate; the utility reduction due to
fracture events; and most cost parameters were varied
by ±30%. The cost of outpatient fracture treatment was
varied by ±50%, due to the higher level of uncertainty
present in the underlying estimates. The linear offset post
alendronate administration was set to 0.4 or 1.6 times the
treatment duration, corresponding to a 2-year or 8-year
linear offset for a treatment duration of 5 years. Persistence
with alendronate treatment was assumed to decline from
100% to either 40% or 80% during year 1, and to decline
further to either 20% or 60% between end of year 1 and the
end of the intended duration of use [49]. The correction for
non-causally related hip fracture-associated deaths was set
to 15% or 50%, and the correction of hip fracture-related
nursing home time for increased general co-morbidity of
nursing home residents was set to 0.6 or 1.0, the latter
representing no correction. The probability of a new
nursing home admission after hip fracture was set to 10%
or 25% [12]. The discount rate was set to 0% or 6%.
Subsequently, probabilistic sensitivity analyses were run
on the main scenarios. Triangular distributions, based on
the base case values and the above described ranges of
variation, were used to vary the above-listed parameters
jointly. As an exception, a uniform distribution was used to
vary the correction of hip fracture-related nursing home
time for increased general co-morbidity of nursing home
residents, in the absence of published values. The discount
rate was not varied in probabilistic sensitivity analysis.
Technical implementation
The model was implemented using TreeAge Pro 2006
Suite® (TreeAge, Williamstown, USA). TreeAge’s option
to independently seed each model iteration allowed to
greatly reduce the amount of random variation present in
the simulation results. Additional statistical analyses were
performed in Stata/SE®, version 9 (Stata Corporation,
College Station, USA). Main scenarios and univariate
sensitivity analyses were based on 100,000 simulated
persons per arm, for each scenario. Probabilistic sensitivity
analyses used 500 different sets of input parameters
(randomly drawn from the above-mentioned triangular
distributions) and 2,000 simulated persons per set of input
parameters and arm [27].
Model validation
All validations performed on the previously published
model [12] retained their validity. Expected gender- and
age-specific prevalences of osteoporosis and osteopenia
were reproduced correctly. After model calibration, the
overall fracture incidence rates found for a cohort followed
for the rest of their lives from age 50 onwards, without
alendronate treatment, deviated only slightly from the
incidence rates calculated from the previously published
model (deviations in women: hip fracture 0.7%; vertebral
fracture 0.2%; distal forearm fracture 0.2%, deviations in
men: hip fracture −0.3%; vertebral fracture 0.0%; distal
forearm fracture −3.3%). A simulation of 50,000 virtual
persons receiving alendronate, under the assumption of
perfect persistence and a relative risk of fracture of 0.5,
correctly reduced fracture incidences by 50%. Two
scenarios mimicking the previously published models
of Christensen et al. [23] and Johnell et al. [25] delivered
similar results in terms of expected relative fracture risk
reduction. Calculation of 95% confidence intervals based
on bias-corrected bootstrapping using 1,000 repetitions
confirmed standard errors for the main outcomes of interest
to be sufficiently small compared to effect sizes. (Data not
shown).
Results
Results for the primary outcome measure, incremental cost
per QALY gained (ICUR), are shown in Table 3, for both
genders. Table 3 covers the base case scenarios (where all
persons entered the model at age 50) as well as the
alternative scenarios (where all persons entered the model
at the main screening age; to enhance comparability with
results published earlier by Schousboe et al. [27]). The
incremental costs of, and QALYs gained with a screen-and-
treat strategy compared to no intervention, assuming model
entry at age 50 and 5 years of intended treatment with
alendronate if applicable, under realistic persistence
assumptions, are shown for women and men in Table 4.
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ICUR results were better when model entry was at the
main screening age (i.e., when the possibility of earlier
diagnosis and treatment was disregarded); better in women
than in men; better if perfect persistence was assumed; and
better if the intended treatment duration was extended from
5 to 10 years under realistic persistence assumptions.
However, the latter was not observed when the main
screening age was set to 85 years.
In women, the ICUR of the screen-and-treat strategy
compared to no intervention was less than CHF 50,000 for a
main screening age of 75 years or higher, in the base case
scenario. In the alternative scenarios, ICUR results were
below or around CHF 50,000 for all main screening ages
considered. Although the alternative scenarios showed overall
improved cost-effectiveness results, the relative rank order of
the assessed strategies remained identical. An additional
analysis under realistic persistence assumptions showed that,
in women, a screen-and-treat strategy using a main screening
age of 70 years lead to ICURs of CHF 49,101 and CHF
42,141 for 5 and 10 years of intended alendronate treatment,
respectively. However, the screen-and-treat approach did not
appear to be cost-effective for a main screening age of 65 years
or below, or in men.
The impact of univariate sensitivity analysis on the
ICUR is shown in Table 5, for a representative scenario
(women; model entry at age 50; main screening age
75 years; intended duration of alendronate treatment 5 years;
realistic persistence). For this scenario, parameter changes
favouring the comparator strategy yielded moderate
increases of the ICUR, which remained below or very
close to CHF 50,000 in all instances. Variation of the risk
reduction achieved with alendronate, of the duration of the
residual alendronate effect after the end of drug adminis-
tration, and of the cost of drug treatment had the strongest
impact. The parameters which exerted the smallest influ-
ence were the correction for increased general morbidity of
persons admitted to nursing homes, the probability of a new
nursing home admission after hip fracture, and the cost of
outpatient fracture treatment.
For this same scenario, probabilistic sensitivity analysis
indicated that the cost-effectiveness criterion of CHF
50,000 per QALY gained was met in 79% of cases, with
a 95% confidence interval for the ICUR reaching from cost-
saving to CHF 79,525 per QALY gained (Fig. 1). Under
identical assumptions, but with the main screening age set
to 65 years, the CHF 50,000 per QALY threshold was only
reached in 16% of the cases.
Discussion
The present study demonstrates that, from the perspective
of the Swiss health care system, mass bone densitometry
screening at or after age 70, plus subsequent alendronate
therapy for 5 or 10 years (screen-and-treat strategy for
osteoporosis and osteopenia), is a cost-effective interven-
tion in women, with an ICUR around or below CHF 50,000
per QALY gained. This finding is based on realistic
assumptions with respect to persistence with drug treatment
and takes into account the impact of diagnostic and
treatment activities before the age of mass screening,
induced by “pre-screening age” fracture occurrence. It is
Table 4 Incremental cost of and quality-adjusted life years (QALYs)
gained with a screen-and-treat strategy compared to no intervention,
per 1,000 persons
Women Men
Main screening age 65 years
QALYs gained (years) 8.34 2.05
Incremental cost (CHF) 591,920 405,190
Main screening age 75 years
QALYs gained (years) 9.85 2.04
Incremental cost (CHF) 348,750 251,570
Main screening age 85 years
QALYs gained (years) 5.44 1.01
Incremental cost (CHF) 153,340 120,210
Specifications: model entry at age 50; intended duration of alendro-
nate treatment 5 years; realistic persistence
Table 3 Incremental cost-utility ratio in CHF per quality-adjusted life
year gained, for women and men, by main screening age
Main
screening
age
5 years
alendronate,
persistence
100%
5 years
alendronate,
realistic
persistence
10 years
alendronate,
realistic
persistence
Women
Age at model entry, 50 years
65 years 55,729 70,995 61,280
75 years 24,170 35,4121 30,155
85 years 19,433 28,170 34,341
Age at model entry equals main screening age
65 years 45,545 55,533 46,805
75 years 5,045 11,904 7,245
85 years Cost-saving Cost-saving Cost-saving
Men
Age at model entry, 50 years
65 years 149,682 197,460 162,509
75 years 95,559 123,094 113,178
85 years 93,184 118,945 123,973
Age at model entry equals main screening age
65 years 135,638 176,670 147,991
75 years 60,269 85,911 73,526
85 years 30,763 48,268 50,413
1 CHF 21,502 per quality-adjusted life year gained if assuming no
diagnostic or treatment activity before the age of mass screening.
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hence in line with the stated hypothesis. In contrast, a
screen-and-treat strategy for osteoporosis and osteopenia
does not appear to be cost-effective in men.
Increasing the intended duration of alendronate treatment
from 5 to 10 years leads to improved ICUR results in most
cases. However, for a main screening age of 85 years, this
was no longer true. At this age, all-cause mortality rates are
very high and cost savings due to avoided fracture events
may no longer be able to outweigh the additional cost of
further treatment.
Our results demonstrate further that in situations where
fixed upfront costs (not influenced by persistence; such as
screening costs) have a substantial role, sub-optimal persis-
tence can have a relevant negative impact on ICUR results.
Our screen-and-treat strategy assumed, in contrast to
current clinical practice in Switzerland and other countries
[58], that all persons fracturing before the main screening
age would immediately be assessed, and treated with
alendronate if osteopenic or osteoporotic. Not allowing for
such “pre-screening age” diagnostic and treatment activities
leads to improved cost-effectiveness results because on
average, alendronate is now administered at a higher age
and when fracture incidences are also higher, at the cost of not
protecting an easily identifiable risk group at an earlier age.
To our knowledge, the only other modelling study
assessing a mass screen-and-treat strategy for osteoporosis
was recently published by Schousboe et al. [27]. These
authors compared the combination of DXA screening plus
alendronate treatment from a US perspective. Their ap-
proach was conceptionally close to ours, with some
remarkable differences. The present model used Swiss or
European data whenever available; all scenarios were
assessed for women and for men; the strategies modelled
took into account osteopenia in addition to osteoporosis;
and realistic assumptions were made with respect to
persistence with alendronate treatment in the base case
analysis. Most importantly, we observed the target popula-
tion from age 50 onwards (and not from the age of mass
screening onwards, which scotomizes any diagnostics
performed earlier, and treatments administered earlier, due
to fracture occurrence before the main screening age). This
scotomization and a related difficulty to individually model
“pre-screening age” fracture-induced changes in health-
related quality of life and utility may have lead to an
overestimation of the cost-effectiveness of the screen-and-
treat approach, in particular when a very high main
screening age was chosen. In order to clarify this point,
we performed alternative assessments with model entry at
Table 5 Univariate sensitivity analysis of incremental cost-utility ratio for women
Parameter varied Range of variation Favours
screening/
alendronate use
Baseline Favours
comparator
strategy
Fracture risk (average population
risk)
+30%/−30% 22,775 35,412 45,512
Fracture risk, effect of alendronate Relative reduction of risk, +30%/−30% 18,062 35,412 52,543
Duration of effect of alendronate after
end of administration
Linear offset, 1.6/0.4 times duration of administration 25,409 35,412 50,131
Persistence (persons taking drug) Decline to 40%/80% in year 1, further decline to 20%/
60% between end of year 1 and end of intended
duration of use
30,149 35,412 46,374
Causally related hip fracture-
associated deaths
50%/15% 25,525 35,412 41,904
Correction for increased general
morbidity in persons admitted to
nursing homes
1.0/0.6 34,751 35,412 37,395
Probability of new nursing home
admission after hip fracture
10%/25% 31,334 35,412 37,989
Disutility factors Relative utility reduction, +30%/−30% 29,272 35,412 44,812
Cost of alendronate −30%/+30% 22,002 35,412 48,822
Cost of diagnostic work-up before
initiation of alendronate therapy
−30%/+30% 29,988 35,412 40,836
Cost of inpatient treatment inclusive
of nursing home stays
+30%/−30% 28,325 35,412 42,499
Cost of outpatient fracture treatment −50%/+50% 34,289 35,412 36,535
Discount rate 0%/6% 20,904 35,412 47,807
Specifications: model entry at age 50, main screening age 75 years; intended duration of alendronate treatment 5 years; realistic persistence
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the main screening age. The resulting set of more favourable
ICUR values was entirely consistent with the results reported
by Schousboe et al. [27]. In both cases, the gain in cost-
effectiveness achieved by choosing a higher main screening
age was distinctly bigger than in our analyses observing the
target population from age 50 onwards. Observing the
target population from the age of mass screening onwards
only, or otherwise disregarding diagnostic and treatment
activities before the main screening age, tends to overesti-
mate cost-effectiveness in general, and the advantages of
choosing a high screening age in particular.
This study has some limitations. The proposed results
and conclusions are model-based, which always implies a
simplification of reality. This remains true although we
adapted our published model [12] to incorporate the
screening and diagnostic process (in contrast to other
modelling studies addressing the cost-effectiveness of
alendronate [23, 25]); to take into account increases in
relative fracture risk in persons with anamnestic fractures or
with low BMD; and to correct for the discrepancy between
fracture-associated deaths and deaths causally related
to fracture [23, 25]. The co-morbidity patterns of osteopo-
rotic fracture patients are likely to differ from those of the
general population and we implemented a correction for
increased general morbidity in persons who were admitted
to a nursing home post hip fracture. However, little detailed
knowledge is available on this topic, which may have a
significant impact on patient outcomes and on the cost-
effectiveness of intervention which could not be adequately
reflected in our model and deserves further research.
The model did not encompass all types of osteoporotic
fractures but was limited to three typical fracture sites.
About 18–25% of osteoporotic fractures were shown to
occur at other skeletal sites not considered in the present
analysis [4]. This may have led to a certain underestimation
of the cost-effectiveness of the screen-and-treat approach.
We made realistic assumptions with respect to
persistence with drug treatment, but in order to limit
complexity, it was assumed that no further drug costs
were accrued by those persons who stopped taking the
drug prematurely. Moreover, given that alendronate is
currently taken as a weekly tablet, the possibility of
additional compliance effects (such as reduced effec-
tiveness due to omission of individual doses or taking
the drug in the wrong way) was neglected. This may
have caused a certain overestimation of the cost-
effectiveness of the screen-and-treat approach.
Only some of our model inputs could be based on published
or official Swiss data [12]. Other model inputs had to be
derived from various European or US sources, had to be
based on expert opinion, or were subject to relevant
uncertainty otherwise (e.g., persistence with drug treatment;
residual treatment effect after the end of drug administration).
However, univariate and probabilistic sensitivity analyses
confirmed the robustness of the ICUR results. Based on
variation within a ±30% range, the risk reduction achieved
with drug treatment was the most sensitive single parameter.
The applicability of our results is in essence limited to
Switzerland, as Swiss cost and resource use data were used.
Some transferability to other industrialised countries with
similar cost and age structures can be assumed, but cannot
be taken for granted. Transferability to other treatments of
osteoporosis may neither be without problems. Separate
calculations would be required, based on a thorough
assessment of reported effect sizes, related levels of
empirical evidence, and other related input parameters (e.g.,
expected persistence).
Finally, this study did not assess the cost-effectiveness of
scenarios involving a pre-selection of sub-populations at
high risk of osteoporosis. Earlier studies have shown that
selective case-finding based on a combination of risk
factors, with or without radiographic absorptiometry,
Fig. 1 Probabilistic sensitivity analysis of incremental cost-utility
ratio of DXA-based screening and subsequent alendronate treatment,
compared to no intervention, for women. Specifications: model entry
at age 50; intended duration of alendronate treatment 5 years; realistic
persistence; main screening ages 65 years (top) and 75 years (bottom).
Slant lines represent the cost-effectiveness threshold of CHF 50,000
per quality-adjusted life year gained
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provided a better sensitivity and specificity in identifying
women with underlying osteoporosis than the currently
accepted criteria for reimbursement of DXA measurements
in Switzerland [59]. In addition, the pre-selection of women
and men at highest risk of osteoporosis, and who should
therefore undergo BMD measurement by DXA, based on
the determination of their 10-year absolute fracture risk
may considerably improve the cost-effectiveness of the
population-based screen-and-treat approach [60–64]. More
research work is required in this field.
In Switzerland, as in other European countries, universal
screening for osteoporosis with bone densitometry using
DXA is not recommended and patient identification solely
relies on case-finding strategies based on anamnestic
fractures and/or other risk factors for osteoporosis. For the
USA, medical interventions have been considered as cost-
effective from a societal point of view if their cost was
below USD 50,000–100,000 per QALY gained [33].
Allowing for different price structures in the USA vs.
Switzerland, the cost-effectiveness threshold adopted here,
of CHF 50,000 per QALY, is at the lower end of this range,
and was used in an assessment only taking into account
direct medical costs. It corresponds to 0.9 times the Swiss
gross domestic product (GDP) per capita in the year 2000
(while use of a factor of 1.4–2.1 times the GDP per capita
has been tentatively estimated for the UK [65]), and must,
thus, be considered as conservative. With this restrictive
assumption, this is the first European study to demonstrate
that population-based screening with bone densitometry by
DXA and subsequent alendronate treatment in the presence
of osteoporosis, or of anamnestic fracture and osteopenia, is
cost-effective in women from age 70 onwards and should,
therefore, be regarded as a valid option from a Swiss health
care system point of view.
Generic alendronates may become available in Switzer-
land in the future. By Swiss law, no cost-effectiveness
assessment of new generics is required if they are marketed
at least 30% below the price of the original drug [66].
Based on their lower price, such generic alendronates may
contribute to further improve the cost-effectiveness of the
screen-and-treat option. Our corresponding univariate sen-
sitivity analysis result of CHF 22,002 per QALY gained
reflects this theoretical potential, if it is assumed that the
clinical efficacy, tolerability and safety of the original
compound will be matched.
Although the incremental cost-utility ratio remains
superior if a high main screening age is chosen, the
difference seen is distinctly smaller than reported earlier
[27], leaving more room for the notion that it may be more
important from an individual, but also from a societal
perspective to avoid fracture events at a younger rather than
at a later age, despite higher absolute budget implications
due to differences in the size of the populations to be
screened. If and for which population segments the cost-
effectiveness of the screen-and-treat approach can be
further improved, e.g., by pre-selection of eligible candi-
dates for screening based on clinical risk factor profiles,
should be subject to further research.
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